Scroll for more

Investors

 

Stock Information

Track the recent performance of Sucampo shares on the NASDAQ Global Market (symbol SCMP).

 
 

Stock Information

STOCK PRICE Feb 13 2017 1:35PM

DAILY HIGH

DAILY LOW

VOLUME

11.650.10 (0.87%)

11.75

11.50

248628


 
 
 

Historic Stock Look Up

 
 

The stock information provided is for informational purposes only and is not intended for trading purposes. The stock information is provided by NASDAQ.  Sucampo Pharmaceuticals, Inc. does not maintain or provide information directly to this service. Stock information is delayed approximately 20 minutes.

 
 

For investor inquiries please contact:

Silvia Taylor

Senior Vice President, Investor Relations and Corporate Affairs

Email: investor@sucampo.com

Phone: +1-240-223-3718

 
Contact Us
 
Tel: +1-301-961-3400
 

Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of specialized medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA – and a late-stage pipeline of product candidates in clinical development for orphan disease areas. VTS-270 is a mixture of 2-hydroxypropyl-B-cyclodextrins with a specific compositional fingerprint that has been granted orphan designation in the U.S. and Europe and is in a pivotal Phase 2/3 clinical trial for the treatment of Niemann-Pick Disease Type C-1. Sucampo has an option for the North American rights to CPP1- x/sulindac, which is in Phase 3 development for the treatment of familial adenomatous polyposis and has been granted orphan drug designation in the U.S. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan and Switzerland.